Dar Arshud, Tipu Masroor, Townsend Hugh, Potter Andy, Gerdts Volker, Tikoo Suresh
Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan SK, Canada S7N 5E3.
Avian Dis. 2015 Dec;59(4):518-24. doi: 10.1637/11202-052815-Reg.1.
Inclusion body hepatitis (IBH) is one of the major infectious diseases adversely affecting the poultry industry of the United States and Canada. Currently, no effective and safe vaccine is available for the control of IBH virus (IBHV) infection in chickens. However, based on the excellent safety and immunogenic profiles of experimental veterinary vaccines developed with the use of new generation adjuvants, we hypothesized that characterization of vaccine formulations containing inactivated IBHV or its capsid protein hexon as antigens, along with poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) and avian beta defensin 2 (ABD2) as vaccine adjuvants, will be helpful in development of an effective and safe vaccine formulation for IBH. Our data demonstrated that experimental administration of vaccine formulations containing inactivated IBHV and a mixture of PCEP with or without ABD2 as an adjuvant induced significantly higher antibody responses compared with other vaccine formulations, while hexon protein-based vaccine formulations showed relatively lower levels of antibody responses. Thus, a vaccine formulation containing inactivated IBHV with PCEP or a mixture of PCEP and ABD2 (with a reduced dosage of PCEP) as an adjuvant may serve as a potential vaccine candidate. However, in order to overcome the risks associated with whole virus inactivated vaccines, characterization of additional viral capsid proteins, including fiber protein and penton of IBHV along with hexon protein in combination with more new generation adjuvants, will be helpful in further improvements of vaccines against IBHV infection.
包涵体肝炎（IBH）是对美国和加拿大家禽业产生不利影响的主要传染病之一。目前，尚无有效且安全的疫苗可用于控制鸡群中的IBH病毒（IBHV）感染。然而，基于使用新一代佐剂开发的实验性兽用疫苗具有出色的安全性和免疫原性，我们推测以灭活的IBHV或其衣壳蛋白六邻体作为抗原，并将聚[二（羧基苯氧基乙基）磷酸钠]（PCEP）和禽β-防御素2（ABD2）作为疫苗佐剂的疫苗制剂特性研究将有助于开发一种有效且安全的IBH疫苗制剂。我们的数据表明，与其他疫苗制剂相比，实验性给予含有灭活IBHV以及含或不含ABD2的PCEP混合物作为佐剂的疫苗制剂可诱导显著更高的抗体反应，而基于六邻体蛋白的疫苗制剂显示出相对较低的抗体反应水平。因此，含有灭活IBHV与PCEP或PCEP和ABD2混合物（降低PCEP剂量）作为佐剂的疫苗制剂可能是一种潜在的疫苗候选物。然而，为了克服全病毒灭活疫苗相关风险，对包括IBHV的纤维蛋白和五邻体以及六邻体蛋白在内的其他病毒衣壳蛋白与更多新一代佐剂进行特性研究，将有助于进一步改进针对IBHV感染的疫苗。
